secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-01-23T23:59:59+00:00
Accession:  0000320017-25-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata reports Phase 2 ASCEND Cohort A: mOS 12.68 vs 9.72 months; 4 complete responses
--------------------------------------------------------------------------------

- Cohort A: median OS of 12.68 months for certepetide plus chemo vs 9.72 months for placebo plus chemo.
- Complete responses: 4 of 65 (6.2%) in certepetide group; 0 of 28 in placebo group.
- Median PFS was 5.5 months in both arms; 6-month PFS trend favored certepetide.
- Cohort B (two-dose regimen) data expected in coming months; full data from both cohorts to follow.
- Lisata plans to advance certepetide to Phase 3 in early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000004/0000320017-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000004/clbs-20250122.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer